GlassScriptPhysician profile
Mauli R Dalal
NPI 1669935524
$2,480.19
in general payments reported to CMS, 2019-2025
28 companies · $720 in 2025
The $720 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.85 · 2022: $97.71 · 2023: $822 · 2024: $815 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,357.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $846.13 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $283.68 | 2022-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $235.62 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Aimmune Therapeutics, INC. | $221.97 | 2024-2025 | Zenpep |
| Medtronic, INC. | $110.86 | 2023 | Interstim |
| Nestle Healthcare Nutrition INC. | $97.56 | 2023 | |
| Glaxosmithkline, LLC. | $81.48 | 2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lundbeck LLC | $63.16 | 2023-2025 | Rexulti |
| Exact Sciences Corporation | $61.90 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.97 | 2023-2025 | Jardiance |
| Esperion Therapeutics, INC. | $51.89 | 2025 | Nexletol |
| Stryker Corporation | $50.30 | 2025 | Mako |
| Novartis Pharmaceuticals Corporation | $42.89 | 2021-2023 | |
| Novo Nordisk INC | $28.93 | 2023 | Ozempic, Rybelsus |
| Dexcom, INC. | $25.10 | 2024 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $22.11 | 2023 | Rexulti |
| Viatris Specialty LLC | $21.79 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $19.59 | 2025 | Inspire |
| Mylan Specialty L.P. | $19.40 | 2024 | Yupelri |
| Verona Pharma, INC. | $18.82 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $17.96 | 2024 | Nuzyra |
| Evofem Biosciences, INC. | $16.46 | 2024 | |
| Sumitomo Pharma America, INC. | $15.87 | 2024 | Gemtesa |
| Pfizer INC. | $14.66 | 2023 | |
| Organon LLC | $14.23 | 2025 | Nexplanon |
| Cashflow Solutions, LLC | $14.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.57 | 2024 | |
| Abbvie INC. | $13.20 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mauli Dalal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.